Tempest Therapeutics reported third-quarter 2025 results and moved further into a formal review of strategic alternatives, effectively shifting from...

Senseonics reported third-quarter 2025 revenue of $8.1 million, up 90% year over year, as U.S. new patient starts jumped...

Generation Bio reported third-quarter 2025 results with cash and marketable securities at $89.6 million, down from $185.2 million at...

ElectroCore posted record third-quarter 2025 revenue of $8.7 million, up 33% year over year, and lifted full-year guidance to...

MediPharm Labs will rotate its board at year-end, with Shelley Potts stepping down on December 31, 2025, and former...

XOMA Royalty Corporation will acquire Generation Bio for $4.2913 per share in cash, plus a contingent value right that...

Humacyte has published the first prospective long-term outcomes for its off-the-shelf biologic vascular conduit, Symvess, in extremity arterial trauma,...

Galapagos released topline data from two phase 3-enabling studies of its oral, selective TYK2 inhibitor GLPG3667. In dermatomyositis, the...

Scilex Holding Company has opened the claim process for its Dream Bowl 2026 Meme Coin, a token distribution to...

Galapagos will wind down its cell therapy business following a strategic review and reported a nine‑month 2025 net loss...